Last reviewed · How we verify
NCT07364630: BIORESCUE
A Multicenter, Prospective, Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.
Phase 4 trial testing Tri-Membrane Wrap™ DFU in Diabetic Foot Ulcer in 50 participants. Currently enrolling.
1 January 2027
Quick facts
| Lead sponsor | BioLab Holdings |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 2 January 2026 |
| Primary completion | 1 January 2027 |
| Estimated completion | 1 January 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Tri-Membrane Wrap™ DFU
- Membrane Wrap™ DFU
- Membrane Wrap-Lite™ DFU
- Membrane Wrap-Hydro™ DFU
- Tri-Membrane Wrap™ VLU
- Membrane Wrap™ VLU
- Membrane Wrap-Lite™ VLU
- Membrane Wrap-Hydro™ VLU
Conditions studied
- Diabetic Foot Ulcer — all drugs for Diabetic Foot Ulcer →
- Foot Ulcer Chronic — all drugs for Foot Ulcer Chronic →
- DFU — all drugs for DFU →
- Ulcer Foot — all drugs for Ulcer Foot →
Sponsor
BioLab Holdings
Who can join
18 and older, any sex, with Diabetic Foot Ulcer or Foot Ulcer Chronic. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Percentage of Wound Closure
Time frame: 1-12 Weeks
The percentage of target ulcers achieving complete wound closure in 12 weeks.
Sponsor's own description
The study is a multicenter, prospective, controlled modified multi-platform trial assessing the efficacy of human placental membrane products and standard of care in the management of nonhealing diabetic foot ulcers and venous leg ulcers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07364630
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetic Foot Ulcer
Currently open trials in the same condition.
- NCT07161830 — Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers · NA · recruiting
- NCT07396376 — Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers · Phase 1, PHASE2 · recruiting
- NCT07291817 — Intermittent Negative Pressure for Patients With Diabetic Foot Ulcers (INPRESS) Study · NA · recruiting
- NCT07209358 — EDX110 Randomized Control Trial for Treatment of DFUs · NA · recruiting
- NCT06938685 — Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers · NA · recruiting
Other BioLab Holdings trials
Trials by the same sponsor.
- NCT06544564 — Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07364630 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BioLab Holdings
- Last refreshed: 5 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07364630.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing